Polares Medical Secures $50m to Advance MRace Mitral Valve Implant

Polares Medical has raised $50m in a Series C financing round to support the clinical development of its MRace posterior leaflet replacement system for treating mitral regurgitation (MR).

The oversubscribed round included investors such as DC Global Ventures and Lumination Partners. The funding will help advance ongoing clinical trials of the MRace device in the US, Europe and Australia.

MRace is designed to restore the function of the posterior leaflet of the mitral valve, preventing the backward flow of blood from the left ventricle to the left atrium. Untreated severe MR can lead to complications such as stroke, hypertension and heart rhythm disorders.

The posterior leaflet replacement introduces a new approach to transcatheter mitral therapies, traditionally dominated by surgery or TEER procedures.

Devices like the MitraClip from Abbott Laboratories currently lead the market, while Cardiac Dimensions is also developing competing mitral repair technologies as demand for minimally invasive treatments continues to grow.

04-03-2026